Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: A prospective naturalistic study

References

• Ford ES, Gilles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J Am Med Assoc 2002;16:356–9.
   Google Scholar
• ADA, APA, AACE, NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267–72.
   Google Scholar
• Susce MT, Villanueva N, Diaz FJ, De Leon J. Obesity and associated complications in patients with severe mental illness: a cross-sectional survey. J Clin Psychiatry 2005;66:167–73.
   PubMed Web of Science ®Google Scholar
• Lamberti JS, Olson D, Crilly JF, Olivares T, C WG, Tu X . Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273–6.
   PubMed Web of Science ®Google Scholar
• von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones PB. Schizophrenia and physical health problems. Acta Psychiatr Scand 2009;119(Suppl 438):15–21.
   Google Scholar
• Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment. The metabolic syndrome. Life Sci 2002;71:239–57.
   PubMed Web of Science ®Google Scholar
• Correll CU, Fredrickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 2006;67:575–83.
   PubMed Web of Science ®Google Scholar
• Holt RIG. Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. Brit J Psychiatry 2004;184(Suppl 47):s55–63.
   Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, Niskanen L, Kumpusalo E, Tuomilehto J . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002;288:2709–16.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1–93.
   PubMed Web of Science ®Google Scholar
• Blair SN, Church TS. The fitness, obesity, and health equation. J Am Med Assoc 2004;292:1232–4.
   PubMed Web of Science ®Google Scholar
• Djousse L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. J Am Med Assoc 2009;302:394–400.
   PubMed Web of Science ®Google Scholar
• Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486–91.
   PubMed Web of Science ®Google Scholar
• Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol. 2011;51(5):631–8.
   Google Scholar
• Baptista T. Body weight gain induced by antipsychotic drugs: mechanism and management. Acta Psychiatr Scand 1999;100:3–16.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Dreiher J, Klang S, Munitz H, Cohen AD, Goldfracht M. Antipsychotics and diabetes: An age-related association. Ann Pharmacother 2008;42:1316–22.
   PubMed Web of Science ®Google Scholar
• Smith M, Hopkins D, Peveler RC, Holt RIG, Woodward M, Ismail K. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2008;192:406–11.
   PubMed Web of Science ®Google Scholar
• Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863–7.
   PubMed Web of Science ®Google Scholar
• Malone M. Medications associated with weight gain. Ann Pharmacother 2005;39:2046–55.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006;5:523–37.
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:591–8.
   PubMed Web of Science ®Google Scholar
• Wei F, Crain AL, Whitebird RR, Godlevsky OV, O'Connor PJ. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol. An observational cohort study. CNS Drugs 2009;23:857–65.
   Google Scholar
• Luef G, Rauchenzauner M, Waldmann M, Sturm W, Sandhofer A, Seppi K . Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Res 2009;86:42–7.
   PubMed Web of Science ®Google Scholar
• Mintzer S, Skidmore CT, Abidin CJ, . Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009;65:448–56.
   PubMed Web of Science ®Google Scholar
• Verrotti A, Manco R, Agostinelli S, Coppola G, Chiarelli F. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia. 2010;51(2):268–73.
   PubMed Web of Science ®Google Scholar
• Cohn TA, Remington G, Zipursky R, Azad A, Connolly P, Wolever TM Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006;51:382–6.
   PubMed Web of Science ®Google Scholar
• Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004;184(Suppl 47):s64–6.
   Google Scholar
• Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio P. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996;37:68–73.
   PubMed Web of Science ®Google Scholar
• Ryan MCM, Flanagan S, Kinsella U, . The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004;74:1999–2008.
   PubMed Web of Science ®Google Scholar
• Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry 2004;184(Suppl 47):s76–9.
   Google Scholar
• Golden SH, Lazo M, Carnethon MR. Examing a bidirectional association between depressive symptoms and diabetes. J Am Med Assoc 2008;299:2751–9.
   PubMed Web of Science ®Google Scholar
• Regenold WT, Thapar RK, Manaro C, Gavirnemi S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19–26.
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417–20.
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, Chandler L, Cappelleri JC, Infante MC . Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686–96.
   PubMed Web of Science ®Google Scholar
• Citrome L, Holt RIG, Zachry WM, Clewell JD, Orth PA, Karagianis JL . Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593–603.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009;302:1765–73.
   PubMed Web of Science ®Google Scholar
• Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain. Drug Safety 2006;29:303–19.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, McCann S, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001;46:273–81.
   PubMed Web of Science ®Google Scholar
• Meyer JM. Serum lipids. Effects of antipsychotics. In: Managing metabolic abnormalities in the psychiatrically ill. Bermudes RA, Keck PE, McElroy SL. Washington, DC: American Psychiatric Publishing; 2006. p. 239–76.
   Google Scholar
• Wirshing DA, Boyd JA, Meng LR, Meng LR, Ballon JS, Marder SR . The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856–65.
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Shaw J, Group ftIETFC. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–62.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D . Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399–404.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. The ICD-10 classification of mental and behavioural disorders. Geneva: WHO; 1992.
   Google Scholar
• Allison DB, Loebel AD, Lombardo I, Romano SJ, Siu CO. Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials: Effect modification or regression to the mean. Psychiatry Res 2009;170:172–6.
   PubMed Web of Science ®Google Scholar
• Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166:345–53.
   PubMed Web of Science ®Google Scholar
• Paton C, Esop R, Young C, Taylor DM. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299–305.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Young C, Esop R, Paton C, Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;185:152–6.
   PubMed Web of Science ®Google Scholar
• Kim B, Kim SJ, Son JI, Joo YH. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric patients. J Affect Disord 2008;105:45–52.
   PubMed Web of Science ®Google Scholar
• Megna JL, Kunwar AR, Wade MJ. A retrospective study of weight changes and the contributing factors in short term adult psychiatric inpatients. Ann Clin Psychiatry 2006;18:163–7.
   PubMedGoogle Scholar
• Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767–70.
   PubMed Web of Science ®Google Scholar
• Baptista T, Ng YK, Beaulieu S. Novel antipsychotics and severe hyperlipidemia: comments on the Meyer paper. J Clin Neuropsychopharmacol 2002;22:536–7.
   Google Scholar
• Basson BR, Kinon B, J, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231–8.
   PubMed Web of Science ®Google Scholar
• Simon V, Van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70:1041–50.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(Suppl 1):20–7.
   Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain – a systematic review. Acta Psychiatr Scand 2000;101:416–32.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Stahl S. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4–14.
   PubMed Web of Science ®Google Scholar
• Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. Int Clin Psychopharmacol 2005;20:105–12.
   Google Scholar
• Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 2006;26:405–8.
   Google Scholar
• Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J . An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002;59:1021–6.
   PubMed Web of Science ®Google Scholar
• Rettenbacher MA, Ebenbichler CF, Hofer A, Kemmler G, Baumgartner S, Edlinger M . Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol 2006;21:369–72.
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher MA, Fleischhacker W . Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007;61:1356–70.
   PubMed Web of Science ®Google Scholar
• Tschoner A, Engl J, Rettenbacher MA, Edlinger M, Kaser S, Tataczyk T . Effects of six second generation antipsychotics on body weight and metabolism – risk assessment and results from a prospective study. Pharmacopsychiatry 2009;42:29–34.
   PubMed Web of Science ®Google Scholar
• Wu R-R, Zhao J-P, Liu Z-N, Zhai J-G, Guo X-F, Guo W-B . Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186:572–8.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28–35.
   PubMed Web of Science ®Google Scholar
• Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA . Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008;28:132–7.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry 2007;68(Suppl 6):14–23.
   Google Scholar
• Rosenberg M, Haass M. Leitlinien der Lipidtherapie. Internist 2005;46:S11–17.
   Google Scholar
• Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E . Glucose metabolism in patients with schizophrenia treated with Olanzapine or Quetiapine: A frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67:789–97.
   Google Scholar
• Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP . Abnormalities in Glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337–45.
   PubMed Web of Science ®Google Scholar
• van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A . Major changes in glucose metabolism, including new-onsetdiabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472–9.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001;62(Suppl 27):5–9.
   Google Scholar